Start-Up Previews, November 2014
The emerging life sciences companies profiled in the November issue of Start-Up: ImmuneXcite, Inivata, Lumoptik, NanoSomiX, and Scholar Rock.
You may also be interested in...
VEGF inhibitors have revolutionized the treatment of age-related macular degeneration, but there’s no getting around the need for lifelong, monthly injections straight into the eye. Lumoptik Inc. has developed a precision navigation system that may allow for more effective, prolonged drug delivery, resulting in less frequent injections over the same time period.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.